"Net sales increased by 16.5% in the fourth quarter, following growth in all business areas and regions. Organic growth accounted for 10.1%, acquisitions for 5% and currency for 1.5%," says Mattias Perjos, President & CEO at
"Despite a weaker order intake, the existing order book, and the dialogue we have with customers lead us to expect organic sales growth of 2-5% for 2024. The two acquisitions completed in Q4 2023 are expected to contribute with 3-5% sales growth in 2024," says Mattias Perjos, President & CEO at
Even though sales increased, the adjusted EBITA margin was lower than 2022, mainly due to the quality costs for the quality improvement work in Acute Care Therapies that has been ongoing since the second quarter of 2023. The margin was negatively impacted by a generally unfavorable geographic and product-related mix and higher costs for input goods and employees.
"Free cash flow increased in Q4, and our strong financial position remains intact, providing us with a solid foundation for continued investment and growth," says Mattias Perjos.
October - December 2023 in brief- Net sales increased by 10.1% and the order intake declined by 2.4% organically.
-
Adjusted gross profit amounted to
SEK 4,596 M (4,153) and the margin was 46.4% (48.9). -
Adjusted EBITA amounted to
SEK 1,318 M (1,317) and the margin was 13.3% (15.5). -
Adjusted earnings per share amounted to
SEK 3.11 (3.35). -
Free cash flow amounted to
SEK 976 M (708) -
The acquisitions of
Healthmark and HPNE were completed -
Events after the end of the quarter:
-
Agneta Palmér appointed new CFO as of
March 31, 2024
January - December 2023 in brief- Net sales increased by 6.4% and the order intake declined by 1.6% organically.
-
Adjusted gross profit amounted to
SEK 15,533 M (14,361) and the margin was 48.8% (50.8). -
Adjusted EBITA amounted to
SEK 3,887 M (4,281) and the margin was 12.2% (15.1). -
Adjusted earnings per share amounted to
SEK 9.19 (10.90). -
Free cash flow amounted to
SEK 1,623 M (2,261). -
A dividend per share of
SEK 4.40 (4.25) is proposed.
-
Agneta Palmér appointed new CFO as of
March 31, 2024
- Net sales increased by 6.4% and the order intake declined by 1.6% organically.
-
Adjusted gross profit amounted to
SEK 15,533 M (14,361) and the margin was 48.8% (50.8). -
Adjusted EBITA amounted to
SEK 3,887 M (4,281) and the margin was 12.2% (15.1). -
Adjusted earnings per share amounted to
SEK 9.19 (10.90). -
Free cash flow amounted to
SEK 1,623 M (2,261). -
A dividend per share of
SEK 4.40 (4.25) is proposed.
A conference call will be held on
To participate via teleconference, please register via this link. After registration, you will be provided with telephone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
During the conference call a presentation will be held. To access the presentation through webcast, please use this link. A recorded version can be accessed here for 3 years.
Media contact:
Phone: +46 (0)10 335 0043
Email: lars.mattsson@getinge.com
This information is such that
About
With a firm belief that every person and community should have access to the best possible care,
https://news.cision.com/getinge/r/getinge-year-end-report-2023--strong-sales-and-healthy-cash-flow---but-margins-impacted-by-quality-c,c3920620
https://mb.cision.com/Main/942/3920620/2576877.pdf
https://mb.cision.com/Public/942/3920620/9d28dd7513d13555.pdf
(c) 2024 Cision. All rights reserved., source